Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Neurogene Inc.

NGNE · Nasdaq · CIK 0001404644 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

8 Form 4 transaction lines observed in the same window
7 sales · 1 option, withholding, award, gift or other lines

Last qualifying purchase2024-11-26 · AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P. · $1.3M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Cvijic Christine MikailPresident and CFO
▼▼▼▼▼
McMinn RachelChief Executive Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-11-26 · AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P..

Recent Form 4 activity

0Purchases
17Sales
5Other Form 4 lines
14SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING7 sale line(s) · context only
OTHER1 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,974,749
Previous report
3,280,172
Avg daily volume
423,989
Days to cover
11.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-11-26AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.Purchase (P)Common Stock48,770USD 25.83USD 1,259,623SEC filing ↗
2024-11-22McMinn RachelPurchase (P)Common Stock47,500USD 20.40USD 969,000SEC filing ↗
2024-11-22Cvijic Christine MikailPurchase (P)Common Stock24,000USD 20.48USD 491,520SEC filing ↗
2023-08-17667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock166,942USD 0.69USD 115,190SEC filing ↗
2023-08-16667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock229,600USD 0.68USD 156,128SEC filing ↗
2023-08-15667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock1,888,800USD 0.63USD 1,190,132SEC filing ↗
2021-08-25DRACHMAN JONATHAN GPurchase (P)Common Stock25,000USD 6.45USD 161,250SEC filing ↗
2021-08-24DRACHMAN JONATHAN GPurchase (P)Common Stock100,000USD 6.11USD 611,000SEC filing ↗
2021-06-04DRACHMAN JONATHAN GPurchase (P)Common Stock10,000USD 9.61USD 96,100SEC filing ↗
2021-06-03DRACHMAN JONATHAN GPurchase (P)Common Stock40,000USD 9.48USD 379,200SEC filing ↗
2020-07-07667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock424,000USD 15.25USD 6,466,000SEC filing ↗
2020-04-02Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock39,300USD 11.37USD 446,938SEC filing ↗
2020-04-01Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock42,500USD 11.10USD 471,675SEC filing ↗
2020-03-31Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock30,000USD 10.31USD 309,375SEC filing ↗
2020-03-30Green Jeremy; Redmile Group, LLCPurchase (P)Common Stock32,500USD 9.94USD 323,047SEC filing ↗

Form 4 evidence

22 transaction lines in the latest 365-day window; 110 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-22McMinn RachelOption exercise / conversion (M)Common Stock756USD 25.32USD 19,142SEC filing ↗
2026-07-07Cvijic Christine MikailSale (S)Common Stock4,200USD 36.13USD 151,746SEC filing ↗
2026-07-06Cvijic Christine MikailSale (S)Common Stock600USD 36.02USD 21,612SEC filing ↗
Show recent Form 4 evidence (16 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-22McMinn RachelOption exercise / conversion (M)Common Stock756USD 25.32USD 19,142SEC filing ↗
2026-07-07Cvijic Christine MikailSale (S)Common Stock4,200USD 36.13USD 151,746SEC filing ↗
2026-07-06Cvijic Christine MikailSale (S)Common Stock600USD 36.02USD 21,612SEC filing ↗
2026-07-02Cvijic Christine MikailSale (S)Common Stock4,061USD 34.82USD 141,424SEC filing ↗
2026-07-01Cvijic Christine MikailSale (S)Common Stock739USD 34.06USD 25,170SEC filing ↗
2026-05-06Cvijic Christine MikailSale (S)Common Stock9,600USD 31.25USD 300,048SEC filing ↗
2026-03-26McMinn RachelSale (S)Common Stock3,352USD 22.07USD 73,979SEC filing ↗
2026-03-26Jordan JulieSale (S)Common Stock828USD 21.89USD 18,125SEC filing ↗
2026-03-26Cvijic Christine MikailSale (S)Common Stock2,558USD 21.62USD 55,304SEC filing ↗
2026-03-13Cvijic Christine MikailSale (S)Common Stock4,045USD 20.81USD 84,178SEC filing ↗
2026-03-13Cobb StuartSale (S)Common Stock6,797USD 20.81USD 141,446SEC filing ↗
2026-02-27Cvijic Christine MikailSale (S)Common Stock4,800USD 25.11USD 120,528SEC filing ↗
2026-02-20McMinn RachelAward / grant (A)Common Stock25,900USD 0.00USD 0SEC filing ↗
2026-02-20Jordan JulieAward / grant (A)Common Stock4,900USD 0.00USD 0SEC filing ↗
2026-02-20Cvijic Christine MikailAward / grant (A)Common Stock22,000USD 0.00USD 0SEC filing ↗
2026-02-20Cobb StuartAward / grant (A)Common Stock16,500USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNGNE
CIK0001404644
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history110 transaction lines from 2020-03-27 to 2026-09-22
33 P purchase lines · 56 S sale lines · 21 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.